Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 5/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1026811 | 0.98 | GRIN2B (0.53) | GRIN2BSIGMAR1DRD3DRD2DRD4 | |
| Benzene SCHEMBL27334501 | 0.96 | GRIN2B (0.56) | GRIN2BSIGMAR1DRD3DRD2DRD4 | |
| SCHEMBL10293234 | 0.86 | MAOA (0.68) | GRIN2BSIGMAR1DRD3DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL7383661 | 0.85 | MAOA (0.66) | GRIN2BSIGMAR1DRD3DRD2DRD4 | |
| SCHEMBL14198148 | 0.84 | DRD2 (0.49) | GRIN2BSIGMAR1DRD3DRD2DRD4 | |
| SCHEMBL1792787 | 0.83 | GRIN2B (0.61) | GRIN2BSIGMAR1DRD3DRD2DRD4 | |
| SCHEMBL10533911 | 0.82 | DRD2 (0.48) | GRIN2BDRD3DRD2DRD4MTNR1A | |
| Hydrochloric Acid SCHEMBL10616548 | 0.81 | DRD2 (0.47) | GRIN2BDRD3DRD2DRD4MTNR1A | |
| SCHEMBL5203096 | 0.78 | GRIN2B (0.52) | GRIN2BSIGMAR1MAOAMAOB | |
| SCHEMBL23378804 | 0.78 | DRD2 (0.44) | GRIN2BSIGMAR1DRD3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| WO-2022120207-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-06 | — | — | US | disclosed |
| WO-2021072203-A1 | TGFBETAR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2020247860-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200345804-A1 | NOVEL AGENTS TARGETING INHIBITOR OF APOPTOSIS PROTEINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-11-05 | — | — | US | disclosed |
| WO-2019195278-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2018102885-A1 | MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2018-06-14 | — | — | WO | disclosed |
| WO-2017120194-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-07-13 | — | — | WO | disclosed |
| EP-2427425-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | ANGION BIOMEDICA CORPORATION (US) | 2008-03-06 | — | — | US | disclosed |
| US-7282608-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2007-10-16 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | GRIN2B 1412/4885SIGMAR1 2780/4885DRD3 991/4885 |
| US-20070027147-A1 | Biarylurea derivatives | CDK6, CDK4, CCNI | GRIN2B 3559/4885SIGMAR1 2868/4885DRD3 1909/4885 |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | GRIN2B 1412/4885SIGMAR1 2780/4885DRD3 991/4885 |
| US-20200345804-A1 | NOVEL AGENTS TARGETING INHIBITOR OF APOPTOSIS PROTEINS | XIAP, BIRC2, BIRC5 | GRIN2B 4580/4885SIGMAR1 4429/4885DRD3 4820/4885 |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, ACE | GRIN2B 2343/4885SIGMAR1 4414/4885DRD3 1490/4885 |
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | GRIN2B 4541/4885SIGMAR1 4523/4885DRD3 4058/4885 |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | TGFBR2, ASGR1, TGFBR1 | GRIN2B 2776/4885SIGMAR1 2970/4885DRD3 4458/4885 |
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | HGF, MET, HDGF | GRIN2B 4166/4885SIGMAR1 2716/4885DRD3 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.